BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

by bizlift | Jan 23, 2020 | BlackThorn Press Releases, Portfolio News

BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders

by bizlift | Dec 11, 2019 | BlackThorn Press Releases, Portfolio News

BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders

by bizlift | Oct 23, 2019 | BlackThorn Press Releases, Portfolio News

BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as CEO to Lead New Stage Growth

by bizlift | Oct 21, 2019 | BlackThorn Press Releases, Portfolio News

BlackThorn Therapeutics Appoints Healthcare Technology Innovator, Monique Levy, as Chief Strategy Officer

by bizlift | Sep 9, 2019 | BlackThorn Press Releases, Portfolio News

BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health

by bizlift | Jun 13, 2019 | BlackThorn Press Releases, Portfolio News